Peptide radiopharmaceutical developer Diatech has changed itsname to Diatide in a move designed to link itself more closelyto the technology it is developing. The Londonderry, NH-basedcompany announced the change this month after approval by itsboard of
Peptide radiopharmaceutical developer Diatech has changed itsname to Diatide in a move designed to link itself more closelyto the technology it is developing. The Londonderry, NH-basedcompany announced the change this month after approval by itsboard of directors.
Diatide is developing peptide-based imaging and therapy agentsthat are labeled with technetium-99m (SCAN 8/30/95). The firmplans to file a new drug application in 1997 for its lead product,an agent for the detection of deep vein thrombosis.
Assessing MACE Risk in Women: Can an Emerging Model with SPECT MPI Imaging Have an Impact?
December 9th 2024In research involving over 2,200 women who had SPECT MPI exams, researchers found that those who had a high score with the COronary Risk Score in WOmen (CORSWO) model had a greater than fourfold higher risk of major adverse coronary events (MACE).